Gyre Therapeutics Overview: Gyre Therapeutics Inc. is a biopharmaceutical company focusing on organ fibrosis treatments, with its flagship product ETUARY being the first approved treatment for idiopathic pulmonary fibrosis in China.
Financial Performance: The company reported second-quarter sales of $26.78 million, falling short of expectations, but anticipates revenue growth in 2025 driven by new product launches and existing sales.
Hydronidone Development: Gyre's lead asset, hydronidone, has shown promising results in clinical trials for liver fibrosis and is expected to enter Phase 2 assessment in the U.S. by late 2025, with plans for accelerated approval in China.
Market Potential: Analysts predict significant market potential for hydronidone, estimating it could generate approximately $6 billion in annual sales by 2033, similar to the success anticipated for Madrigal Pharmaceuticals' recent liver disease treatment.
MDGL
$554.57+Infinity%1D
Analyst Views on MDGL
Wall Street analysts forecast MDGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 543.25 USD with a low forecast of 392.00 USD and a high forecast of 650.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast MDGL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 543.25 USD with a low forecast of 392.00 USD and a high forecast of 650.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 560.550
Low
392.00
Averages
543.25
High
650.00
Current: 560.550
Low
392.00
Averages
543.25
High
650.00
BofA
Jason Zemansky
Neutral
maintain
$456 -> $581
2025-12-16
New
Reason
BofA
Jason Zemansky
Price Target
$456 -> $581
2025-12-16
New
maintain
Neutral
Reason
BofA analyst Jason Zemansky raised the firm's price target on Madrigal Pharmaceuticals to $581 from $456 and keeps a Neutral rating on the shares. The firm is increasing its near-term Rezdiffra forecasts after having conducted a small prescriber survey, but remains below long-term consensus, the analyst tells investors.
B. Riley
William Wood
NULL -> Buy
maintain
$560 -> $670
2025-12-11
Reason
B. Riley
William Wood
Price Target
$560 -> $670
2025-12-11
maintain
NULL -> Buy
Reason
B. Riley analyst William Wood raised the firm's price target on Madrigal Pharmaceuticals to $670 from $560 and keeps a Buy rating on the shares. MASH is now valued using a risk-adjusted approach aligned with recent M&A deals, reflecting peak-year sales of $4.5B extended by loss of exclusivity protection and the Rezdiffra/'2086 combo strategy, the analyst tells investors in a research note. Early GLP-1 adoption trends and strong patient-level script growth support market expansion, while disciplined opex and modest gross-to-net adjustments underpin significant near-term free cash flow generation, the firm says.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$568 -> $620
2025-11-21
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$568 -> $620
2025-11-21
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Madrigal Pharmaceuticals to $620 from $568 and keeps a Buy rating on the shares. The firm increased penetration assumptions for Rezdiffra after speaking with six key opinion leaders. The leaders reported "robust real-world uptake," with current F2/F3 penetration of liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis averaging 23% in high-volume centers and longer-term expectations of 10%-20%, the analyst tells investors in a research note. Despite pressure from weight loss drugs, the leaders view Rezdiffra as an "effective, liver-directed, oral backbone therapy with broader expansion possibilities based on the future F4c data," contends H.C. Wainwright.
Oppenheimer
Jay Olson
Outperform
maintain
$600 -> $650
2025-11-20
Reason
Oppenheimer
Jay Olson
Price Target
$600 -> $650
2025-11-20
maintain
Outperform
Reason
Oppenheimer analyst Jay Olson raised the firm's price target on Madrigal Pharmaceuticals to $650 from $600 and keeps an Outperform rating on the shares. The firm is encouraged by recent updates including several presentations at AASLD that strengthen Rezdiffra's profile and increase its enthusiasm for commercial opportunities in F2-F3 plus F4c patients.
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
